Last $2.86 USD
Change Today +0.04 / 1.42%
Volume 54.0K
ERB On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 8:04 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

erba diagnostics inc (ERB) Snapshot

Open
$2.79
Previous Close
$2.82
Day High
$2.97
Day Low
$2.75
52 Week High
01/8/14 - $4.13
52 Week Low
04/28/14 - $1.39
Market Cap
125.9M
Average Volume 10 Days
24.5K
EPS TTM
$0.02
Shares Outstanding
44.0M
EX-Date
--
P/E TM
130.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for ERBA DIAGNOSTICS INC (ERB)

Related News

No related news articles were found.

erba diagnostics inc (ERB) Related Businessweek News

No Related Businessweek News Found

erba diagnostics inc (ERB) Details

ERBA Diagnostics, Inc., through its subsidiaries, develops, manufactures, and markets diagnostic test kits or assays, and automated systems that are used to aid in the detection of disease markers primarily in the areas of autoimmune, infectious diseases, clinical chemistry, hematology, and diabetes testing. It manufactures scientific and laboratory instruments, such as Mago 4, Mago 4S, and Mago Plus systems, which perform tests in an automated mode; sells other diagnostic products in Italy; and develops, manufactures, and markets diagnostic equipment, as well as raw materials, such as antigens that are used in the production of diagnostic kits. The company also develops, manufactures, and markets autoimmune reagents and research products for use by research laboratories and commercial diagnostic manufacturers. In addition, the company provides instruments for blood cell counting and blood analysis; supplies reagents and other consumable materials; sells diabetic testing products, including the DS5 instrument, dispenser, and associated reagent kits, which measure long-term glucose control in diabetic patients; and offers equipment for use in the field of human and veterinary hematology. Further, it manufactures and sells liquid stable, diagnostics chemistry reagents used for in vitro diagnostics testing. The company markets its products through its sales force to hospitals, reference laboratories, clinical laboratories, and research laboratories, as well as to other commercial companies that manufacture diagnostic products in the United States; and through sales representatives and independent agents in Italy, as well as through independent distributors internationally. ERBA Diagnostics, Inc. was founded in 1980 and is headquartered in Miami Lakes, Florida. ERBA Diagnostics, Inc. is a subsidiary of ERBA Diagnostics Mannheim GmbH.

135 Employees
Last Reported Date: 04/14/14
Founded in 1980

erba diagnostics inc (ERB) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $150.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $47.4K
Compensation as of Fiscal Year 2013.

erba diagnostics inc (ERB) Key Developments

ERBA Diagnostics, Inc. Presents at LD Micro Conference, Dec-04-2014 07:30 AM

ERBA Diagnostics, Inc. Presents at LD Micro Conference, Dec-04-2014 07:30 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, United States. Speakers: Mohan Gopalkrishnan, Chief Executive Officer.

ERBA Diagnostics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Revenue Guidance for 2015

ERBA Diagnostics, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. The company recorded quarterly revenue of $6,469,488 and net income of $127,918 for the third quarter of 2014. This compares to revenue of $6,940,713 and net income of $129,229 for the third quarter of 2013. This decrease in revenue is primarily attributed to the affects from sales to Russia and Africa, deferred production related to consolidation of manufacturing and the phasing out of older lower margin products as ERBA Diagnostics shifts toward selling higher margin instruments and consumables. Income from operations was $351,066 for the third quarter of 2014, compared to $78,541 in the third quarter of 2013. Income before provision for income taxes was $157,051 against $156,523 a year ago. For the nine months, the company reported net revenue of $20,381,257 against $20,538,079 a year ago. Income from operations was $1,154,282 as compared to $229,924 a year ago. Income before provision for income taxes was $832,120 against $49,498 a year ago. Net income was $743,944 or $0.01 per diluted share against net loss of $30,490 a year ago. Looking ahead to 2015 and beyond, the company expected further revenue growth to come from a combination of new products are developing or may distribute.

ERBA to Feature New Urinalysis and Diabetes Monitoring Systems

ERBA Diagnostics, Inc. will be featuring two new fully automated diagnostic testing instruments, the Hb-Vario diabetes monitoring system and the Laura XL urinalysis processer, at MEDICA 2014 in Dusseldorf Germany, November 12-15. ERBA Diagnostics will also showcase its comprehensive range of testing products, including the Elisa systems for autoimmune and infectious disease, chemistry analyzers, hematology analyzers, urine analyzers and coagulation systems. The Hb-Vario is an automated HPLC system that is capable of measuring both Glycated hemoglobin (HbA1c) and HbA2 for the monitoring of diabetes. ERBA Diagnostics anticipates launching the product initially in Europe, following CE Mark clearance, followed by a release in select emerging markets. Diabetes continues to be one of the major challenges worldwide to the healthcare industry. The benefits of monitoring HbA1c values to better manage diabetes is well documented in numerous studies and is a key to reducing co-morbidity complications. HbA1c testing is poised to emerge as a popular technology with outpatient clinics and small hospital-based laboratories according to a industry analyst report, which forecasts that the global market for diabetes diagnostics is estimated to reach $26 billion per year by 2015. The Laura XL is a fully automated urinalysis and sedimentation processor with the capability to automate urine strip reading as well as performing sedimentation cell analysis for abnormal samples. ERBA Diagnostics will be the exclusive distributor for the product in the U.S. and Latin America following receipt of regulatory approvals and clearances. Industry analysts have estimated that the worldwide in vitro diagnostics urinalysis market is approximately $600 million per year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ERB:US $2.86 USD +0.04

ERB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $38.40 USD +0.42
Bio-Rad Laboratories Inc $121.31 USD +0.53
Corgenix Medical Corp $0.27 USD 0.00
DiaSorin SpA €33.50 EUR +0.10
Meridian Bioscience Inc $16.96 USD 0.00
View Industry Companies
 

Industry Analysis

ERB

Industry Average

Valuation ERB Industry Range
Price/Earnings 100.0x
Price/Sales 4.5x
Price/Book 6.8x
Price/Cash Flow 86.8x
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ERBA DIAGNOSTICS INC, please visit www.erbadiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.